SOST and posterior cortical atrophy: This is consistent with the cross-sectional study examining serum sclerostin levels in ADT-treated PCa patients, PCa patients without ADT, and healthy controls, where ADT-treated PCa patients had higher levels of sclerostin than the other two groups18.